Phase III Study of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablets in Treatment of Peripheral Sensory Neuropathy in Anti-cancer Chemotherapeutics Induce
This multicenter, randomized, double-blind, placebo-controlled and parallel clinical trial
is to observe the efficacy and safety of the Acetyl-L-Carnitine Hydrochloride enteric-coated
tablets in treatment of peripheral sensory neuropathy that anti-cancer chemotherapeutics
induce.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Changes in peripheral sensory neuropathy grades
Changes in peripheral sensory neuropathy grades after eight weeks treatment
Base and eighth week
Yes
China: Food and Drug Administration
ZHAOKE-2007L03540
NCT01526564
May 2009
May 2010
Name | Location |
---|